Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ionis
Biotech
Otsuka heads to FDA as Ionis-allied ALS drug hits primary goal
A phase 3 study of Otsuka and Ionis’ ALS prospect hit its primary endpoint, positioning the partners to talk to regulators about expedited approvals.
Nick Paul Taylor
Sep 22, 2026 9:22am
Ultragenyx fails ph. 3 Angelman test as shares tumble
Sep 3, 2026 7:10am
Biogen advances Alzheimer’s tau program despite midphase miss
May 14, 2026 8:35am
Ionis axes eye disease from targets of Roche-partnered prospect
Aug 1, 2024 8:06am
Intellia showcases durability of one-and-done HAE option
Jun 2, 2024 8:00am
AstraZeneca drops GOLDILOX and the porcupine in R&D update
Apr 25, 2024 3:24am
